The stock of Immune Design Corp (NASDAQ:IMDZ) is a huge mover today! The stock increased 7.12% or $0.54 during the last trading session, hitting $8.12. About 107,606 shares traded hands. Immune Design Corp (NASDAQ:IMDZ) has declined 24.28% since February 29, 2016 and is downtrending. It has underperformed by 36.49% the S&P500.
The move comes after 6 months positive chart setup for the $210.23M company. It was reported on Oct, 4 by Barchart.com. We have $17.78 PT which if reached, will make NASDAQ:IMDZ worth $250.17M more.
Analysts await Immune Design Corp (NASDAQ:IMDZ) to report earnings on November, 10. They expect $-0.68 EPS, down 83.78% or $0.31 from last year’s $-0.37 per share. After $-0.71 actual EPS reported by Immune Design Corp for the previous quarter, Wall Street now forecasts -4.23% EPS growth.
Immune Design Corp (NASDAQ:IMDZ) Ratings Coverage
Out of 2 analysts covering Immune Design (NASDAQ:IMDZ), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Immune Design has been the topic of 4 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The stock of Immune Design Corp (NASDAQ:IMDZ) earned “Buy” rating by Jefferies on Wednesday, August 10. Jefferies initiated Immune Design Corp (NASDAQ:IMDZ) rating on Wednesday, September 9. Jefferies has “Buy” rating and $30 price target. The company was initiated on Tuesday, August 18 by Leerink Swann.
According to Zacks Investment Research, “Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305, and G305 for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma; and G100 for the treatment of patients with merkel cell carcinoma. Immune Design Corp. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.25 in 2016 Q2. Its up 0.21, from 1.04 in 2016Q1. The ratio improved, as 8 funds sold all Immune Design Corp shares owned while 16 reduced positions. 8 funds bought stakes while 22 increased positions. They now own 9.57 million shares or 12.34% less from 10.92 million shares in 2016Q1.
Moreover, Schwab Charles Inv Management has 0% invested in Immune Design Corp (NASDAQ:IMDZ) for 16,243 shares. Pnc Financial Svcs Grp, a Pennsylvania-based fund reported 76 shares. Barclays Public Limited Liability has 264 shares for 0% of their US portfolio. Teacher Retirement System Of Texas holds 0% or 1,129 shares in its portfolio. Wells Fargo Co Mn accumulated 0% or 4,208 shares. Blackrock last reported 3,163 shares in the company. Eventide Asset Lc last reported 180,000 shares in the company. Blackrock Invest Mgmt Limited Liability Company holds 0% or 41,876 shares in its portfolio. State Street Corp holds 207,670 shares or 0% of its portfolio. Rhumbline Advisers last reported 0% of its portfolio in the stock. The Manitoba – Canada-based Great West Life Assurance Can has invested 0% in Immune Design Corp (NASDAQ:IMDZ). The Florida-based Proquest Assocs Iv Lc has invested 6.51% in Immune Design Corp (NASDAQ:IMDZ). Credit Suisse Ag last reported 0% of its portfolio in the stock. Tfs Capital Limited Liability Company accumulated 102,685 shares or 0.15% of the stock. California State Teachers Retirement Systems holds 0% or 23,474 shares in its portfolio.
Insider Transactions: Since July 15, 2016, the stock had 4 insider buys, and 0 selling transactions for $10.26 million net activity. The insider Brady Stephen R bought $10,255. COLEMAN LEWIS W also bought $250,000 worth of Immune Design Corp (NASDAQ:IMDZ) on Tuesday, September 20. COLUMN GROUP L P also bought $5.00M worth of Immune Design Corp (NASDAQ:IMDZ) shares. Another trade for 800,000 shares valued at $5.00 million was bought by Svennilson Peter.
More important recent Immune Design Corp (NASDAQ:IMDZ) news were published by: Globenewswire.com which released: “Immune Design Announces Proposed Public Offering of Common Stock” on September 14, 2016, also Globenewswire.com published article titled: “Immune Design Announces Presentations at the 2016 American Society of Clinical …”, Globenewswire.com published: “Immune Design and Gritstone Oncology Announce Clinical Collaboration for …” on May 09, 2016. More interesting news about Immune Design Corp (NASDAQ:IMDZ) was released by: Zacks.com and their article: “Immune Design (IMDZ) Posts Wider-than-Expected Q2 Loss” with publication date: August 10, 2016.
IMDZ Company Profile
Immune Design Corp., incorporated on February 20, 2008, is a clinical-stage immunotherapy company. The Firm focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Firm is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.